LIVN:NSD-LivaNova PLC (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 80.07

Change

-2.21 (-2.69)%

Market Cap

USD 4.35B

Volume

0.51M

Avg Analyst Target

USD 109.57 (+36.84%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


LivaNova PLC (LIVN) Stock Analysis:
Based on the LivaNova PLC stock forecasts from 4 analysts, the average analyst target price for LivaNova PLC is USD 109.57 over the next 12 months. LivaNova PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of LivaNova PLC is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, LivaNova PLC’s stock price was USD 80.07. LivaNova PLC’s stock price has changed by -3.29 % over the past week, -9.64 % over the past month and +44.95 % over the last year.

About

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lu ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-40.73 (-7.27%)

USD54.53B 105.66 116.79
ALGN Align Technology Inc

-5.18 (-0.83%)

USD48.22B 67.36 43.89
PODD Insulet Corporation

-24.07 (-8.38%)

USD19.55B 2,208.27 215.55
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

-11.81 (-3.78%)

USD13.91B 95.93 46.10
BRKR Bruker Corporation

-2.28 (-2.80%)

USD12.72B 45.92 26.74
TNDM Tandem Diabetes Care Inc

+5.77 (+4.52%)

USD8.30B 376.31 185.23
SWAV ShockWave Medical Inc

-7.40 (-4.29%)

USD6.42B N/A N/A
INMD InMode Ltd

-3.94 (-5.47%)

USD6.24B 40.67 39.23
IART Integra LifeSciences Holdings ..

-0.96 (-1.51%)

USD5.49B 25.06 17.90

ETFs Containing LIVN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.93% 74% C 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.93% 74% C 71% C-
Trailing 12 Months  
Capital Gain 44.95% 80% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.95% 80% B- 82% B-
Trailing 5 Years  
Capital Gain 76.40% 66% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.40% 66% D 65% D
Average Annual (5 Year Horizon)  
Capital Gain 17.47% 40% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.47% 40% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 47.98% 66% D 37% F
Risk Adjusted Return 36.42% 50% F 52% F
Market Capitalization 4.35B 91% A- 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.40 25% F 14% F
Price/Book Ratio 3.32 54% F 38% F
Price / Cash Flow Ratio -54.79 87% B+ 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -30.53% 48% F 36% F
Return on Invested Capital -2.41% 65% D 42% F
Return on Assets 0.27% 73% C 46% F
Debt to Equity Ratio 57.41% 41% F 35% F
Technical Ratios  
Short Ratio 4.75 36% F 30% F
Short Percent 4.34% 40% F 36% F
Beta 0.85 66% D 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector